141 related articles for article (PubMed ID: 20808670)
1. Efficacy of dendritic cells matured early with OK-432 (Picibanil), prostaglandin E2, and interferon-alpha as a vaccine for a hormone refractory prostate cancer cell line.
Yoo C; Do HA; Jeong IG; Park H; Hwang JJ; Hong JH; Cho JS; Choo MS; Ahn H; Kim CS
J Korean Med Sci; 2010 Sep; 25(9):1284-90. PubMed ID: 20808670
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of immunomodulators for maturation of dendritic cells.
Ogihara T; Iinuma H; Okinaga K
Int J Oncol; 2004 Aug; 25(2):453-9. PubMed ID: 15254744
[TBL] [Abstract][Full Text] [Related]
3. Quick generation of fully mature dendritic cells from monocytes with OK432, low-dose prostanoid, and interferon-alpha as potent immune enhancers.
Sakakibara M; Kanto T; Inoue M; Kaimori A; Yakushijin T; Miyatake H; Itose I; Miyazaki M; Kuzushita N; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
J Immunother; 2006; 29(1):67-77. PubMed ID: 16365602
[TBL] [Abstract][Full Text] [Related]
4. Generation of mature dendritic cells fully capable of T helper type 1 polarization using OK-432 combined with prostaglandin E(2).
Sato M; Takayama T; Tanaka H; Konishi J; Suzuki T; Kaiga T; Tahara H
Cancer Sci; 2003 Dec; 94(12):1091-8. PubMed ID: 14662025
[TBL] [Abstract][Full Text] [Related]
5. Interferon-α-inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity.
Koya T; Yanagisawa R; Higuchi Y; Sano K; Shimodaira S
Sci Rep; 2017 Feb; 7():42145. PubMed ID: 28191816
[TBL] [Abstract][Full Text] [Related]
6. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
[TBL] [Abstract][Full Text] [Related]
7. Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes.
Tanaka F; Yamaguchi H; Haraguchi N; Mashino K; Ohta M; Inoue H; Mori M
Int J Oncol; 2006 Nov; 29(5):1263-8. PubMed ID: 17016660
[TBL] [Abstract][Full Text] [Related]
8. Streptococcal preparation OK432 promotes functional maturation of human monocyte-derived dendritic cells.
Itoh T; Ueda Y; Okugawa K; Fujiwara H; Fuji N; Yamashita T; Fujiki H; Harada S; Yoshimura T; Yamagishi H
Cancer Immunol Immunother; 2003 Apr; 52(4):207-14. PubMed ID: 12669245
[TBL] [Abstract][Full Text] [Related]
9. [Antitumor effects and mechanisms of a dendritic cell vaccine which silenced SOCS1 by siRNA, stimulated by OK-432 and pulsed with lysate of HepG2 cells].
Song HF; Zhou J; Pan K; Wang QJ; Wang H; Huang LX; Li YQ; Xia JC
Ai Zheng; 2008 Jul; 27(7):685-91. PubMed ID: 18606059
[TBL] [Abstract][Full Text] [Related]
10. An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA-loaded dendritic cells for cancer vaccination.
Brabants E; Heyns K; De Smet S; Devreker P; Ingels J; De Cabooter N; Debacker V; Dullaers M; VAN Meerbeeck JP; Vandekerckhove B; Vermaelen KY
Cytotherapy; 2018 Sep; 20(9):1164-1181. PubMed ID: 30122654
[TBL] [Abstract][Full Text] [Related]
11. 3-Day monocyte-derived dendritic cells stimulated with a combination of OK432, TLR7/8 ligand, and prostaglandin E
Yi DH; Stetter N; Jakobsen K; Jonsson R; Appel S
Cancer Immunol Immunother; 2018 Oct; 67(10):1611-1620. PubMed ID: 30069688
[TBL] [Abstract][Full Text] [Related]
12. Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells.
Koido S; Hara E; Homma S; Torii A; Mitsunaga M; Yanagisawa S; Toyama Y; Kawahara H; Watanabe M; Yoshida S; Kobayashi S; Yanaga K; Fujise K; Tajiri H
J Immunol; 2007 Jan; 178(1):613-22. PubMed ID: 17182602
[TBL] [Abstract][Full Text] [Related]
13. Streptococcal preparation OK-432 promotes the capacity of dendritic cells (DCs) to prime carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses induced with genetically modified DCs that express CEA.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Iida T; Yamaue H
Int J Oncol; 2008 Feb; 32(2):459-66. PubMed ID: 18202769
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide.
Nakahara S; Tsunoda T; Baba T; Asabe S; Tahara H
Cancer Res; 2003 Jul; 63(14):4112-8. PubMed ID: 12874015
[TBL] [Abstract][Full Text] [Related]
15. OK-432 synergizes with IFN-γ to confer dendritic cells with enhanced antitumor immunity.
Pan K; Lv L; Zheng HX; Zhao JJ; Pan QZ; Li JJ; Weng DS; Wang DD; Jiang SS; Chang AE; Li Q; Xia JC
Immunol Cell Biol; 2014 Mar; 92(3):263-74. PubMed ID: 24296809
[TBL] [Abstract][Full Text] [Related]
16. Streptococcal preparation OK-432: a new maturation factor of monocyte-derived dendritic cells for clinical use.
Kuroki H; Morisaki T; Matsumoto K; Onishi H; Baba E; Tanaka M; Katano M
Cancer Immunol Immunother; 2003 Sep; 52(9):561-8. PubMed ID: 14627128
[TBL] [Abstract][Full Text] [Related]
17. Mature dendritic cells generated from patient-derived peripheral blood monocytes in one-step culture using streptococcal preparation OK-432 exert an enhanced antigen-presenting capacity.
Naito K; Ueda Y; Itoh T; Fuji N; Shimizu K; Yano Y; Yamamoto Y; Imura K; Kohara J; Iwamoto A; Shiozaki A; Tamai H; Shimizu T; Mazda O; Yamagishi H
Int J Oncol; 2006 Jun; 28(6):1481-9. PubMed ID: 16685449
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell gene therapy.
Onaitis M; Kalady MF; Pruitt S; Tyler DS
Surg Oncol Clin N Am; 2002 Jul; 11(3):645-60. PubMed ID: 12487060
[TBL] [Abstract][Full Text] [Related]
19. TNF-α and tumor lysate promote the maturation of dendritic cells for immunotherapy for advanced malignant bone and soft tissue tumors.
Miwa S; Nishida H; Tanzawa Y; Takata M; Takeuchi A; Yamamoto N; Shirai T; Hayashi K; Kimura H; Igarashi K; Mizukoshi E; Nakamoto Y; Kaneko S; Tsuchiya H
PLoS One; 2012; 7(12):e52926. PubMed ID: 23300824
[TBL] [Abstract][Full Text] [Related]
20. Generation of potent cytotoxic T lymphocytes against castration-resistant prostate cancer cells by dendritic cells loaded with dying allogeneic prostate cancer cells.
Hwang EC; Lim MS; Im CM; Kwon DD; Lee HJ; Nguyen-Pham TN; Lee YK; Lee JJ
Scand J Immunol; 2013 Feb; 77(2):117-24. PubMed ID: 23126536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
